Zentalis stock falls as Leerink cuts on data for lead asset
Zentalis Pharmaceuticals (NASDAQ:ZNTL) lost ~21% to reach a new 52-week low on Tuesday after the cancer drug developer updated Phase 1 data for its lead candidate, azenosertib, leading to a downgrade from Leering Partners. With its Q3 2023…
